A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains

BACKGROUND: Most currently approved anti-HIV drugs (e.g., reverse transcriptase inhibitors, protease inhibitors and fusion/entry inhibitors) must act inside or on surface of the target cell to inhibit HIV infection, but none can directly inactivate virions away from cells. Although soluble CD4 (sCD4...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Lu, Pan, Chungen, Li, Yuan, Lu, Hong, He, Wu, Jiang, Shibo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3531269/
https://www.ncbi.nlm.nih.gov/pubmed/23217195
http://dx.doi.org/10.1186/1742-4690-9-104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3531269/
https://www.ncbi.nlm.nih.gov/pubmed/23217195
http://dx.doi.org/10.1186/1742-4690-9-104

Ejemplares similares